排序方式: 共有4条查询结果,搜索用时 0 毫秒
1
1.
Seyed Alireza Javadinia Soodabeh Shahidsales Azar Fanipakdel Mona Joudi-Mashhad Mehrane Mehramiz Sahar Talebian Mona Maftouh Ramin Mardani Seyed Mahdi Hassanian Majid Khazaei Gordon A. Ferns Amir Avan 《Journal of cellular biochemistry》2019,120(5):6833-6840
The Wnt/β-catenin pathway is an important, dysregulated pathway in several tumor types, including pancreatic ductal adenocarcinoma. Although the activation of this pathway is an important component of normal development, its aberrant activation resulting from activating or inactivating mutations in the CTNNB1 gene locus, or in the negative regulators AXIN and APC involving stabilization of β-catenin, and activation of target genes leads to a more aggressive phenotype, suggesting its potential value as a therapeutic target in the treatment of pancreatic ductal adenocarcinoma. A number of small molecule and biologic agents have now been developed for targeting this pathway. This review summarizes the current knowledge about the therapeutic potential of targeting the Wnt pathway with particular emphasis on preclinical/clinical studies in the treatment of pancreatic ductal adenocarcinoma. 相似文献
2.
3.
Ali Taghizadeh Kermani Sare Hosseini Azar Fanipakdel Mona Joudi Mashhad Kambiz Akhavan Rezayat Mahdi Zardadi Arezoo Gholami Seyed Alireza Javadinia Gordon A. Ferns Amir Avan 《Journal of cellular physiology》2019,234(4):4191-4199
The current treatment approaches for esophageal cancer are associated with poor survival, and there are ongoing efforts to find new and more effective therapeutic strategies. There are several reports on the antitumoral effects of low-molecular-weight heparins (LMWHs). We have assessed the possible survival benefit of LMWHs in esophageal malignancies. This was a randomized, single-blind, multicenter, Phase II clinical trial on nonmetastatic esophageal cancer candidate for neoadjuvant chemoradiotherapy. Patients were randomly assigned to the chemoradiotherapy-only arm or chemoradiotherapy plus enoxaparin arm using 1:1 allocation. Radiotherapy was delivered in 1.8-Gy daily fractions to a dose of 50.4 Gy in both groups. Paclitaxel 50 mg/m2 and carboplatin (AUC 2) were administered weekly, concurrent with radiotherapy. In the intervention group, patients received enoxaparin (40 mg) and chemoradiation daily. 4–6 weeks after treatment, all patients underwent esophagectomy. After a median follow up of 7 months, estimated 1 year disease-free survival (DFS) in the intervention group was 78.9% and was 70% in the control groups ( p = 0.5). Toxicity from the experimental treatment was minimal, and there were no treatment-related deaths. A pathologically complete response in intervention and control group was 64.8% and 62.5%, respectively ( p = 0.9). There was a nonsignificant trend toward improved survival by the addition of enoxaparin to the concurrent chemoradiotherapy regimen. However, 1 y DFS of both groups were high as expected. A longer follow-up and a larger sample size are required. 相似文献
4.
Karimi Farzaneh Amiri-Moghaddam Seyedeh Mina Bagheri Zakieh Bahrami Ahmad Reza Goshayeshi Ladan Allahyari Abolghasem Mirsadraee Marjane Fanipakdel Azar Bari Alireza Emadi-Torghabeh Ali Kerachian Mohammad Amin Rahimi Hossein Matin Maryam M. 《Molecular biology reports》2021,48(3):2273-2284
Molecular Biology Reports - Genome-wide association studies have revealed that some single nucleotide polymorphisms at 8q24, such as rs6983267, might be effective in susceptibility to various... 相似文献
1